A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation

Protocol No
FORMA-2102-ONC-102
Principal Investigator
John Charlson
Phase
I/II
Summary
The clinical trial will first investigate FT-2102 given by itself in a few patients to see if it is safe (Phase 1b). If the dose is determined to be safe, more patients will receive FT-2102 alone (Phase 2). After several patients are treated with FT-2102 only, then more patients may receive FT-2102 in combination with other chemotherapies.
Description
A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: